Trends in blood pressure control in hypertensive patients with diabetes mellitus in Japan

Hypertension Research

Volumn 26, Issue 9, 2003, Pages 717-722

  Hirose, Hiroshi ^a   Saito, Ikuo ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

Angiotensin II receptor antagonist; Angiotensin converting enzyme inhibitor; Calcium channel blocker; Diabetes mellitus; Internet survey

Indexed keywords

AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FELODIPINE; IRBESARTAN; LISINOPRIL; LOSARTAN; METOPROLOL; RAMIPRIL;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; E-MAIL; FEMALE; HEALTH SURVEY; HUMAN; HYPERTENSION; INTERNET; JAPAN; MALE; MEDICAL SOCIETY; PHYSICIAN; PRACTICE GUIDELINE; QUESTIONNAIRE; REFERENCE VALUE;

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; DIABETES MELLITUS, TYPE 2; FEMALE; GUIDELINE ADHERENCE; HUMANS; HYPERTENSION; JAPAN; MALE; MIDDLE AGED; PRACTICE GUIDELINES; QUESTIONNAIRES; RECEPTORS, ANGIOTENSIN;

EID: 0141927459     PISSN: 09169636     EISSN: None     Source Type: Journal    
DOI: 10.1291/hypres.26.717     Document Type: Article

References (18)

1. Reaven GM: Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
2. Kaplan NM: The deadly quartet: upper-body obesity, glucose intolerance, hypertriglyceridemia and hypertension. Arch Intern Med 1989; 149: 1514-1520.
3. DeFronzo RA, Ferrannini E: Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173-194.
4. Nakamura T, Tokunaga K, Shimomura I, et al: Contribution of visceral fat accumulation to the development of coronary artery disease in non-obese men. Atherosclerosis 1994; 107: 239-246.
5. American Diabetes Association: Treatment of hypertension in adults with diabetes. Diabetes Care 2002; 25(Suppl 1): S71-S73.
6. Japanese Society of Hypertension Subcommittee for the Management of Hypertension: Guidelines for the management of hypertension for general practitioners. Hypertens Res 2001; 24: 613-634.
7. Zanchetti A, Ruilope LM: Antihypertensive treatment in patients with type-2 diabetes mellitus: what guidance from recent controlled randomized trials? J Hypertens 2002; 20: 2099-2110.
8. Katayama S, Inaba M, Morita T, Awata T, Shimamoto K, Kikkawa R: Blood pressure control in Japanese hypertensives with or without type 2 diabetes mellitus. Hypertens Res 2000; 23: 601-605.
9. Guideline Committee of the Japan Diabetes Society: Japan Diabetes Society guidelines for the management of diabetes based on scientific evidences. J Jpn Diabet Soc 2002; 45 (Suppl 1): 65-75.
10. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413-2446.
11. Guidelines Subcommittee: 1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. J Hypertens 1999; 17: 151-183.
12. Hansson L, Zanchetti A, Carruthers SG, et al: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-1762.
13. Saito I, Kawabe H, Tsujioka M, Hirose H, Shibata H: Trends in pharmacologic management of hypertension in Japan one year after the publication of the JSH 2000 guidelines. Hypertens Res 2002; 25: 175-178.
14. Brenner BM, Cooper ME, DeZeeuw D, et al: Effect of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
15. Lewis EJ, Hunsicker LG, Clarke WR, et al: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
16. Lindholm LH, Ibsen H, Dahlof B, et al: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004-1010.
17. Wright JT, Bakris G, Greene T, et al: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288: 2421-2431.
18. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.